Admac Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 10-12-2024
- Paid Up Capital ₹ 2.68 M
as on 10-12-2024
- Company Age 36 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 24.65 Cr
as on 10-12-2024
- Satisfied Charges ₹ 1.12 Cr
as on 10-12-2024
- Revenue %
(FY 2024)
- Profit -10.66%
(FY 2024)
- Ebitda 14.69%
(FY 2024)
- Net Worth 6.33%
(FY 2024)
- Total Assets 5.49%
(FY 2024)
About Admac Pharma
The Company is engaged in the Real Estate And Construction Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 2.68 M.
The company currently has active open charges totaling ₹24.65 Cr. The company has closed loans amounting to ₹1.12 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramesh Sharma, Sat Malhotra, and Nilesh Batra serve as directors at the Company.
- CIN/LLPIN
U45202CH1988PLC008610
- Company No.
008610
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Aug 1988
- Date of AGM
10 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationU T, Chandigarh
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Admac Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilesh Batra  | Director | 24-Jan-2019 | Current |
| Ramesh Sharma | Director | 07-Jun-2021 | Current |
| Sat Malhotra | Director | 14-May-2021 | Current |
Financial Performance of Admac Pharma.
Admac Pharma Limited, for the financial year ended 2024, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 10.66% decrease in profit. The company's net worth moved up by a moderate rise of 6.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Admac Pharma?
In 2024, Admac Pharma had a promoter holding of 99.02% and a public holding of 0.98%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Admac International Private LimitedActive 16 years 22 daysRamesh Sharma, Sat Malhotra and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 30 Jun 2020 | ₹24.65 Cr | Open |
Bank Of India Creation Date: 15 Mar 2002 | ₹1.20 M | Satisfied |
Bank Of India Creation Date: 19 Mar 1999 | ₹0.20 M | Satisfied |
How Many Employees Work at Admac Pharma?
Unlock and access historical data on people associated with Admac Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Admac Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Admac Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
